Giant Biogene FY2025 net profit fell 7.1% to RMB1.91 billion

Reuters03-19

<a href="https://laohu8.com/S/02367">Giant Biogene</a> FY2025 net profit fell 7.1% to RMB1.91 billion

Giant Biogene published an announcement of annual results for the year ended 31 December 2025.
Revenue fell 0.4% to RMB5.52 billion, while gross profit declined 2.5% to RMB4.43 billion.
Profit before tax decreased 4.4% to RMB2.35 billion, and net profit dropped 7.1% to RMB1.91 billion.
Basic earnings per share fell 12.9% to RMB1.83, while cash and cash equivalents rose more than doubled to RMB6.31 billion.
The board proposed a final dividend of RMB0.5390 per share and a special dividend of RMB0.6714 per share; management said 2025 performance was pressured by intensified industry competition and external headwinds, and the 2026 goal is to return to growth.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Giant Biogene Holding Co Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260319-12059378), on March 19, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620443042?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-19 19:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620443042","market":"nz","top_or_hot":-1,"title":"Giant Biogene FY2025 net profit fell 7.1% to RMB1.91 billion","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/02367\">Giant Biogene</a> FY2025 net profit fell 7.1% to RMB1.91 billion\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Giant Biogene published an announcement of annual results for the year ended 31 December 2025.\n        </li>\n<li>\n          Revenue fell 0.4% to RMB5.52 billion, while gross profit declined 2.5% to RMB4.43 billion.\n        </li>\n<li>\n          Profit before tax decreased 4.4% to RMB2.35 billion, and net profit dropped 7.1% to RMB1.91 billion.\n        </li>\n<li>\n          Basic earnings per share fell 12.9% to RMB1.83, while cash and cash equivalents rose more than doubled to RMB6.31 billion.\n        </li>\n<li>\n          The board proposed a final dividend of RMB0.5390 per share and a special dividend of RMB0.6714 per share; management said 2025 performance was pressured by intensified industry competition and external headwinds, and the 2026 goal is to return to growth.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Giant Biogene Holding Co Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260319-12059378), on March 19, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Giant Biogene FY2025 net profit fell 7.1% to RMB1.91 billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGiant Biogene FY2025 net profit fell 7.1% to RMB1.91 billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-19 19:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/02367\">Giant Biogene</a> FY2025 net profit fell 7.1% to RMB1.91 billion\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Giant Biogene published an announcement of annual results for the year ended 31 December 2025.\n        </li>\n<li>\n          Revenue fell 0.4% to RMB5.52 billion, while gross profit declined 2.5% to RMB4.43 billion.\n        </li>\n<li>\n          Profit before tax decreased 4.4% to RMB2.35 billion, and net profit dropped 7.1% to RMB1.91 billion.\n        </li>\n<li>\n          Basic earnings per share fell 12.9% to RMB1.83, while cash and cash equivalents rose more than doubled to RMB6.31 billion.\n        </li>\n<li>\n          The board proposed a final dividend of RMB0.5390 per share and a special dividend of RMB0.6714 per share; management said 2025 performance was pressured by intensified industry competition and external headwinds, and the 2026 goal is to return to growth.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Giant Biogene Holding Co Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260319-12059378), on March 19, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02367","symbol_name":"巨子生物","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDLg86WP:1","article_id":"2620443042","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620443042","pubTimestamp":1773918194,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Giant Biogene published an announcement of annual results for the year ended 31 December 2025.Revenue fell 0.4% to RMB5.52 billion, while gross profit declined 2.5% to RMB4.43 billion.Profit before tax decreased 4.4% to RMB2.35 billion, and net profit dropped 7.1% to RMB1.91 billion.Basic earnings per share fell 12.9% to RMB1.83, while cash and cash equivalents rose more than doubled to RMB6.31 billion.The board proposed a final dividend of RMB0.5390 per share and a special dividend of RMB0.6714 per share; management said 2025 performance was pressured by intensified industry competition and external headwinds, and the 2026 goal is to return to growth.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Giant Biogene Holding Co Ltd. publish","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02367":"巨子生物","BK1207":"个人用品","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","SG9999004311.SGD":"Nikko AM Shenton Emerging Enterprise Discovery Fund SGD"},"translate_title":"巨人生物基因2025财年净利润下降7.1%至人民币19.1亿元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02367":0.9},"content_text":"Giant Biogene FY2025 net profit fell 7.1% to RMB1.91 billion\n    \n\n\n          Giant Biogene published an announcement of annual results for the year ended 31 December 2025.\n        \n\n          Revenue fell 0.4% to RMB5.52 billion, while gross profit declined 2.5% to RMB4.43 billion.\n        \n\n          Profit before tax decreased 4.4% to RMB2.35 billion, and net profit dropped 7.1% to RMB1.91 billion.\n        \n\n          Basic earnings per share fell 12.9% to RMB1.83, while cash and cash equivalents rose more than doubled to RMB6.31 billion.\n        \n\n          The board proposed a final dividend of RMB0.5390 per share and a special dividend of RMB0.6714 per share; management said 2025 performance was pressured by intensified industry competition and external headwinds, and the 2026 goal is to return to growth.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Giant Biogene Holding Co Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260319-12059378), on March 19, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620443042","isCrawlerRequest":true}